Form 4: Director Madge Shafmaster Receives ProMIS Stock Options

Director Madge K. Shafmaster was granted 16,500 stock options in ProMIS Neurosciences Inc. as part of board compensation.

Summary

• Director Madge K. Shafmaster acquired 16,500 total stock options in ProMIS Neurosciences Inc. on May 20, 2026.
• The grant consists of two tranches: 5,500 options vesting in full on May 20, 2027, and 11,000 options vesting 25% immediately with the remainder vesting ratably over 36 months.
• All options have an exercise price of $10.77 and an expiration date of May 20, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of these options is contingent upon the company's future stock performance exceeding the $10.77 exercise price.

Future Outlook

The options vest over a period of up to three years, signaling the director's continued commitment to the company's long-term strategic goals.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure director retention and alignment with corporate milestones.

Comparison to Industry Standards

• The use of time-based vesting schedules for director options is consistent with standard corporate governance practices for small-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of 5,500 options on May 20, 2027.
• Ongoing monthly vesting of the remaining 11,000 options over the next 36 months.

Key Dates

Keywords

ProMIS Neurosciences, PMN, Form 4, Insider Trading, Stock Options, Director Compensation